


CLAIMS


1. Compound of formula (I) :



wherein:

- 5 ♦ R₁ and R₂ independently of one another represent a group selected from: hydrogen; linear or branched C₁-C₆alkyl optionally substituted by a hydroxyl or a C₁-C₆alkoxy group; C₃-C₆cycloalkyl; trifluoromethyl; linear or branched C₁-C₆alkylene-heterocycloalkyl wherein the heterocycloalkyl group is optionally substituted by a linear or branched C₁-C₆alkyl group;
- 10 or R₁ and R₂ form with the carbon atoms carrying them a C₃-C₆cycloalkylene group,
- ♦ R₃ represents a group selected from: hydrogen; C₃-C₆cycloalkyl; linear or branched C₁-C₆alkyl; -X₁-NR_aR_b; -X₁-N⁺R_aR_bR_c; -X₁-O-R_c; -X₁-COOR_c; -X₁-PO(OH)₂; -X₁-SO₂(OH); -X₁-N₃ and :

$$-X_1-\equiv\text{CH}$$
,
- 15 ♦ R_a and R_b independently of one another represent a group selected from: hydrogen; heterocycloalkyl; -SO₂-phenyl wherein the phenyl may be substituted by a linear or branched C₁-C₆alkyl; linear or branched C₁-C₆alkyl optionally substituted by one or two hydroxyl groups; C₁-C₆alkylene-SO₂OH; C₁-C₆alkylene-SO₂O⁻; C₁-C₆alkylene-COOH; C₁-C₆alkylene-PO(OH)₂; C₁-C₆alkylene-NR_dR_e; C₁-C₆alkylene-N⁺R_dR_eR_f; C₁-C₆alkylene-phenyl wherein the phenyl may be substituted by a C₁-C₆alkoxy group;
- 20 the group:



or R_a and R_b form with the nitrogen atom carrying them a

cycle B₁;


or R_a, R_b and R_c form with the nitrogen atom carrying them a bridged C₃-C₈heterocycloalkyl,

- ♦ R_c, R_d, R_e, R_f, independently of one another represents a hydrogen or a linear or branched C₁-C₆alkyl group,


or R_d and R_e form with the nitrogen atom carrying them a cycle B₂,

or R_d, R_e and R_f form with the nitrogen atom carrying them a bridged C₃-C₈heterocycloalkyl,

- 10 ♦ Het₁ represents a group selected from the following group:



- ♦ Het₂ represents a group selected from:



◆ A₁ is –NH–, –N(C₁–C₃alkyl), O, S or Se,

◆ A₂ is N, CH or C(R₅),


◆ G is selected from the group consisting of:

–C(O)OR_{G3}, –C(O)NR_{G1}R_{G2}, –C(O)R_{G2}, –NR_{G1}C(O)R_{G2}, ~~–NR_{G1}C(O)NR_{G1}R_{G2},
 5 –OC(O)NR_{G1}R_{G2}, –NR_{G1}C(O)OR_{G3}, –C(=NOR_{G1})NR_{G1}R_{G2},
 –NR_{G1}C(=NCN)NR_{G1}R_{G2}, –NR_{G1}S(O)₂NR_{G1}R_{G2}, –S(O)₂R_{G3}, –S(O)₂NR_{G1}R_{G2},
 –NR_{G1}S(O)₂R_{G2}, –NR_{G1}C(=NR_{G2})NR_{G1}R_{G2}, –C(=S)NR_{G1}R_{G2}, –C(=NR_{G1})NR_{G1}R_{G2}, halogen, –NO₂,
 and –CN, in which:~~

– R_{G1} and R_{G2} at each occurrence are each independently selected from the group consisting of
 10 hydrogen, C₁–C₆alkyl optionally substituted by 1 to 3 halogen atoms,
 C₂–C₆alkenyl, C₂–C₆alkynyl, C₃–C₆cycloalkyl, phenyl and –(CH₂)₁₋₄–phenyl;

– R_{G3} is selected from the group consisting of C₁–C₆alkyl optionally substituted by 1 to 3 halogen
 atoms, C₂–C₆alkenyl, C₂–C₆alkynyl, C₃–C₆cycloalkyl, phenyl and –(CH₂)₁₋₄–phenyl; or

R_{G1} and R_{G2}, together with the atom to which each is attached are combined to form a C₃–
 15 C₈heterocycloalkyl; or in the alternative, G is selected from the group consisting of:



wherein R_{G4} is selected from C_1 - C_6 alkyl optionally substituted by 1 to 3 halogen atoms, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl and C_3 - C_6 cycloalkyl,


◆ R_4 represents a hydrogen, fluorine, chlorine or bromine atom, a methyl, a hydroxyl or a methoxy group,

◆ R_5 represents a group selected from: C_1 - C_6 alkyl optionally substituted by 1 to 3 halogen atoms; C_2 - C_6 alkenyl; C_2 - C_6 alkynyl; halogen or $-CN$,

◆ R_6 represents a group selected from:
hydrogen;

$-C_2$ - C_6 alkenyl;

$-X_2-O-R_7$;



$-X_2-NSO_2-R_7$;

$-C=C(R_9)-Y_1-O-R_7$;

C_3 - C_6 cycloalkyl;


C_3 - C_6 heterocycloalkyl optionally substituted by a hydroxyl group;

C_3 - C_6 cycloalkylene- Y_2-R_7 ;

C₃-C₆heterocycloalkylene-Y₂-R₇ group,

an heteroarylene-R₇ group optionally substituted by a linear or branched C₁-C₆alkyl group,


- ♦ R₇ represents a group selected from: linear or branched C₁-C₆alkyl group;
(C₃-C₆)cycloalkylene-R₈; or:



5

wherein Cy represents a C₃-C₈cycloalkyl,


- ♦ R₈ represents a group selected from: hydrogen; linear or branched C₁-C₆alkyl, -NR'_aR'_b;
-NR'_a-CO-OR'_c; -NR'_a-CO-R'_c; -N⁺R'_aR'_bR'_c; -O-R'_c; -NH-X'₂-N⁺R'_aR'_bR'_c;
-O-X'₂-NR'_aR'_b, -X'₂-NR'_aR'_b, -NR'_c-X'₂-N₃ and :



10

- ♦ R₉ represents a group selected from linear or branched C₁-C₆alkyl, trifluoromethyl, hydroxyl,
halogen, C₁-C₆alkoxy,
♦ R₁₀ represents a group selected from hydrogen, fluorine, chlorine, bromine, -CF₃ and methyl,

- ◆ R_{11} represents a group selected from hydrogen, C_1 - C_3 alkylene- R_8 , $-O$ - C_1 - C_3 alkylene- R_8 , $-CO$ - NR_hR_i and $-CH=CH$ - C_1 - C_4 alkylene- NR_hR_i , $-CH=CH$ -CHO, C_3 - C_8 cycloalkylene- CH_2 - R_8 , C_3 - C_8 heterocycloalkylene- CH_2 - R_8 ,
- ◆ R_{12} and R_{13} , independently of one another, represent a hydrogen atom or a methyl group,
- 5 ◆ R_{14} and R_{15} , independently of one another, represent a hydrogen or a methyl group, or R_{14} and R_{15} form with the carbon atom carrying them a cyclohexyl,
- ◆ R_h and R_i , independently of one another, represent a hydrogen or a linear or branched C_1 - C_6 alkyl group,
- 10 ◆ X_1 and X_2 independently of one another, represent a linear or branched C_1 - C_6 alkylene group optionally substituted by one or two groups selected from trifluoromethyl, hydroxyl, halogen, C_1 - C_6 alkoxy,
- ◆ X'_2 represents a linear or branched C_1 - C_6 alkylene,
- ◆ R'_a and R'_b independently of one another, represent a group selected from: hydrogen; heterocycloalkyl; $-SO_2$ -phenyl wherein the phenyl may be substituted by a linear or branched C_1 - C_6 alkyl; linear or branched C_1 - C_6 alkyl optionally substituted by one or two hydroxyl or C_1 - C_6 alkoxy groups; C_1 - C_6 alkylene- SO_2OH ; C_1 - C_6 alkylene- SO_2O^- ; C_1 - C_6 alkylene- $COOH$; C_1 - C_6 alkylene- $PO(OH)_2$; C_1 - C_6 alkylene- $NR'_dR'_e$; C_1 - C_6 alkylene- $N^+R'_dR'_eR'_f$; C_1 - C_6 alkylene- O - C_1 - C_6 alkylene- OH ; C_1 - C_6 alkylene-phenyl wherein the phenyl may be substituted by a hydroxyl or a C_1 - C_6 alkoxy group;
- 20 the group:




- or R'_a and R'_b form with the nitrogen atom carrying them a cycle B_3 ,
- 25 or R'_a , R'_b and R'_c form with the nitrogen atom carrying them a bridged C_3 - C_8 heterocycloalkyl,
- ◆ R'_c , R'_d , R'_e , R'_f , independently of one another, represents a hydrogen or a linear or branched C_1 - C_6 alkyl group,
- or R'_d and R'_e form with the nitrogen atom carrying them a cycle B_4 ,
- 30

or R'_d , R'_e and R'_f form with the nitrogen atom carrying them a bridged C_3 - C_8 heterocycloalkyl,

- ♦ Y_1 represents a linear or branched C_1 - C_4 alkylene,
- ♦ Y_2 represents a bond, -O-, -O- CH_2 -, -O-CO-, -O-SO₂-, -CH₂-, -CH₂-O, -CH₂-CO-,
 5 -CH₂-SO₂-, -C₂H₅-, -CO-, -CO-O-, -CO-CH₂-, -CO-NH-CH₂-, -SO₂-, -SO₂-CH₂-,
 -NH-CO-, -NH-SO₂-,
- ♦ $m=0, 1$ or 2 ,
- ♦ $p=1, 2, 3$ or 4 ,
- ♦ B_1, B_2, B_3 and B_4 , independently of one another, represents a C_3 - C_8 heterocycloalkyl group,
 10 which group can: (i) be a mono- or bi-cyclic group, wherein bicyclic group includes fused,
 bridged or spiro ring system, (ii) can contain, in addition to the nitrogen atom, one or two hetero
 atoms selected independently from oxygen, sulphur and nitrogen, (iii) be substituted by one or
 two groups selected from: fluorine, bromine, chlorine, linear or branched C_1 - C_6 alkyl, hydroxyl,
 -NH₂, oxo or piperidinyl,
- 15 its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable
 acid or base.

2. Compound according to claim 1 wherein Het₁ represents:




- 20 **3.** Compound according to claim 1 or 2 wherein R_1 represents a methyl group and R_2 represents
 a hydrogen atom.
- 4.** Compound according to claim 1 or 2 wherein R_1 and R_2 represent each a methyl group or a
 hydrogen atom.
- 5.** Compound according to claim 1 or 2 wherein R_1 or R_2 represents a linear or branched C_1 -

C₆alkyl optionally substituted by a hydroxyl or a C₁-C₆alkoxy group, preferably a group selected from: methyl, methoxymethyl, hydroxymethyl, ethyl and prop-2-yl.


- 6.** Compound according to claim 1 or 2 wherein R₁ or R₂ represents a C₃-C₆cycloalkyl, preferably a cyclopropyl group.
- 5 **7.** Compound according to claim 1 or 2 wherein R₁ represents a trifluoromethyl group.
- 8.** Compound according to claim 1 or 2 wherein R₂ represents a linear or branched C₁-C₆alkylene-heterocycloalkyl, preferably a (4-methyl-piperazin-1-yl)propyl group.
- 9.** Compound according to claim 1 or 2 wherein R₁ and R₂ form with the carbon atoms carrying them a cyclohexene or a cyclopentene group.
- 10 **10.** Compound according to any of claims 1 to 9 wherein R₃ represents a hydrogen atom or a methyl group.
- 11.** Compound according to any of claims 1 to 9 wherein R₃ represents -X₁-PO(OH)₂, -X₁-SO₂(OH), -X₁-NR_aR_b; -X₁-N⁺R_aR_bR_c, wherein R_a or R_b, or both of them, represent a group selected from C₁-C₆alkylene-SO₂OH, C₁-C₆alkylene-SO₂O⁻ and C₁-C₆alkylene-PO(OH)₂.
- 15 **12.** Compound according to any of claims 1 to 9 wherein R₈ represents -NR'_aR'_b; -N⁺R'_aR'_bR'_c; -NH-X'₂-N⁺R'_aR'_bR'_c, wherein R'_a and R'_b, or both of them, represent a group selected from C₁-C₆alkylene-SO₂OH and C₁-C₆alkylene-PO(OH)₂.
- 13.** Compound according to any of claims 1 to 9 wherein R₃ represents a group selected from: ethyl, propyl; 2-methoxy-ethyl, 2-(morpholin-4-yl)ethyl, 3-(morpholin-4-yl)propyl, 3-diethylamino-propyl, 3-methoxy-propyl, 3-hydroxy-propyl, 3,4-dihydroxy-butyl, 4-methoxy-3-hydroxy-butyl, 4-hydroxy-3-methoxy-butyl, 2,3-dihydroxy-propyl, 4,5-dihydroxy-pentyl, 4-hydroxy-butyl, 3-hydroxy-2-morpholino-propyl, 5-hydroxy-4-methoxy-pentyl, 5-morpholino-4-hydroxy-pentyl, 3-hydroxy-2-methoxy-propyl, 5-[2-(dimethylamino)ethyl-methyl-amino]-4-hydroxy-pentyl, 5-hydroxy-pentyl, 5-methoxy-4-hydroxy-pentyl, 5-(dimethylamino)-4-hydroxy-pentyl, 4-hydroxy-5-(trimethylammonio)pentyl, 5-[3-sulfonate-propyl-dimethyl-ammonio]-4-hydroxy-pentyl, 4-hydroxy-5-(methylamino)pentyl, 3-carboxy-propyl, 5-[methyl(4-piperidyl)amino]pentyl, 5-(2-
- 20
- 25

morpholinoethylamino)pentyl, 5-[2-(4-methyl-piperazin-1-yl)ethylamino)pentyl, 4-[2-(4-methyl-piperazin-1-yl)ethylamino)butyl, 4-hydroxy-5-[methyl-[2-(methylamino)ethyl]amino]pentyl, 5-[2-(diethylamino)ethylamino]-4-hydroxy-pentyl, 5-(4-Amino-1-piperidyl)-4-hydroxy-pentyl, 4-hydroxy-5-piperazin-1-yl-pentyl, 5-[2-(1-piperidyl)ethylamino]pentyl, 4-(4-Amino-1-piperidyl)butyl, 4-[2-(diethylamino)ethylamino]butyl, 5-(4-Amino-1-piperidyl)pentyl, 4-[methyl-[2-(methylamino)ethyl]amino]butyl, 4-(2-morpholinoethylamino)butyl, 4-[2-(4-methyl-piperazin-1-yl)ethylamino)butyl, 4-[(1-methyl-4-piperidyl)amino]butyl, 5-[2-(diethylamino)ethylamino]pentyl, 4-piperazin-1-ylbutyl, 4-(methylamino)butyl, 5-piperazin-1-ylpentyl, 5-[methyl-[2-(methylamino)ethyl, 5-aminopentyl, 4-aminobutyl, 5-(methylamino)pentyl, 5-[3-(4-methylpiperazin-1-yl)propylamino]pentyl, 4-hydroxy-5-[methyl(2-phosphonoethyl)amino]pentyl, 6-(dimethylamino)hexyl, 3-(dimethylamino)propyl, 2-(trimethylammonio)ethyl, 3-(trimethylammonio)propyl, 2-(dimethylamino)ethyl, 4-(dimethylamino)butyl, 5-[3-sulfonate-propyl-dimethyl-ammonio]pentyl, 4-(trimethylammonio)butyl, 4-hydroxy-5-quinuclidin-1-ium-1-yl-pentyl, 4-hydroxy-5-(1-aza-4-azoniabicyclo[2.2.2]octan-4-yl)pentyl, 4-hydroxy-5-(4-methylmorpholin-4-ium-4-yl)pentyl, 5-(trimethylammonio)pentyl, 4-hydroxy-5-(1-methylpiperidin-1-ium-1-yl)pentyl, 5-(1,4-dimethylpiperazin-1-ium-1-yl)-4-hydroxy-pentyl, 6-(trimethylammonio)hexyl, 5-[3-hydroxypropyl(dimethyl)ammonio]pentyl, 5-[2-hydroxyethyl(dimethyl)ammonio]pentyl, 5-[carboxymethyl(dimethyl)ammonio]pentyl, 5-[carboxymethyl(dimethyl)ammonio]pentyl, 3-phosphonopropyl, 3-[3-sulfonate-propyl-dimethyl-ammonio]propyl, 3-sulfopropyl, 4-sulfobutyl, 4-phosphonobutyl, 4-carboxybutyl, 3-aminopropyl, 3-azidopropyl, pent-4-yn-1-yl, 4-aminobutyl, 4-azidobutyl, hex-5-yn-1-yl, 5-azidopentyl.

14. Compound according to any of claims 1 to 13 wherein Het₂ represents:




15. Compound according to any of claims 1 to 13 wherein Het₂ represents:




16. Compound according to claim 14 or 15 wherein R₆ represents a hydrogen atom.

17. Compound according to claim 14 wherein R_6 represents a $-X_2-O-R_7$ group wherein X_2 is a propylene group.


18. Compound according to claim 17 wherein R_7 represents the following group:



19. Compound according to claim 17 wherein R_7 represents the following group:




20. Compound according to claim 18 or 19 wherein R_8 represents a group selected from: dimethylamino, methylamino, methylethylamino, diethylamino, methyl[2-(methylamino)ethyl]amino, (2-hydroxyethyl)(methyl)amino, 4-morpholinyl, pyrrolidin-1-yl, 1-piperidyl, [(*tert*-butoxy)carbonyl](methyl)amino, hydroxyl, bis(3-sulfopropyl)amino, 3-sulfopropylamino, methyl(3-sulfopropyl)amino, methyl(*p*-tolylsulfonyl)amino, (4-methoxyphenyl)methyl-methyl-amino, 2-(dimethylamino)ethylamino and :




21. Compound according to claim 18 or 19 wherein R_8 represents a group selected from: 3-piperazin-1-yl, 4-methylpiperazin-1-yl, 3-hydroxypropyl(methyl)amino, [(3*S*)-3,4-dihydroxybutyl]-methyl-amino, 3-hydroxypropylamino, [(3*S*)-3,4-dihydroxybutyl]amino, 4-hydroxybutyl(methyl)amino, [(3*R*)-3,4-dihydroxybutyl]-methyl-amino, 4-hydroxybutylamino, [(3*R*)-3,4-dihydroxybutyl]amino.

22. Compound according to claim 17 wherein R_7 represents:



wherein R_{11} is selected from dimethylcarbamoyl, 3-(dimethylamino)propyl, 3-(methylamino)propyl, 3-(methylamino)propyl.


- 23.** Compound according to claim 14 wherein R_6 represents a C_3 - C_6 heterocycloalkylene- Y_2 - R_7 group wherein the heterocycloalkylene group is selected from:




24. Compound according to claim 23 wherein R_7 is selected from: methyl, methylethyl, *tert*-butyl, 2-methylpropyl and phenyl, preferably phenyl.

25. Compound according to claim 14 or 15 wherein R_6 represents $-C=C(R_9)-Y_1-O-R_7$ wherein Y_1 is a methylene group.


- 26.** Compound according to claim 14 or 15 wherein R_6 represents:




27. Compound according to claim 26 wherein R_7 represents a group selected from :



wherein R_8 represents a group selected from: hydrogen, 2-(methylamino)ethoxy and:



28. The compound according to claim 26 wherein R_7 represents a group selected from :



wherein R_8 represents a group selected from: 2-(dimethylamino)ethoxy, 2-[(2-sulfoethyl)amino]ethoxy, 2-[methyl(2-sulfoethyl)amino]ethoxy, 2-(3-hydroxypropylamino)ethoxy, 2-(3-methoxypropylamino)ethoxy, 2-morpholinoethoxy, 2-(2-carboxyethylamino)ethoxy, 2-[(3-hydroxyphenyl)methylamino]ethoxy, 2-(methylamino)ethoxy, 2-pyrrolidin-1-ylethoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 2-(4-hydroxybutylamino)ethoxy, 2-piperazin-1-ylethoxy, 2-[3-hydroxypropyl(methyl)amino]ethoxy, 2-[4-hydroxybutyl(methyl)amino]ethoxy; 2-[[3-hydroxy-2-(hydroxymethyl)propyl]amino]ethoxy; 2-[bis(3-hydroxypropyl)amino]ethoxy.

29. A compound according to claim 1 selected in the following group:

- 2-({6-[(1,3-Benzothiazol-2-yl)amino]-5-methylpyridazin-3-yl}(4-hydroxybutyl)amino)-5-(3-{2-fluoro-4-[3-(methylamino)prop-1-yn-1-yl]phenoxy}propyl)-1,3-thiazole-4-carboxylic

acid,

- 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-methyl-amino]-5-[3-[4-[3-(dimethylamino)prop-1-ynyl]-2-fluoro-phenoxy]propyl]thiazole-4-carboxylic acid,
- 2-({6-[(1,3-Benzothiazol-2-yl)amino]-5-methylpyridazin-3-yl}(methyl)amino)-5-(3-{2-fluoro-4-[3-(methylamino)prop-1-yn-1-yl]phenoxy}propyl)-1,3-thiazole-4-carboxylic acid,
- 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-(3,4-dihydroxybutyl)amino]-5-[3-[2-fluoro-4-[3-(methylamino)prop-1-ynyl]phenoxy]propyl]thiazole-4-carboxylic acid,
- 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-(3-hydroxy-4-methoxy-butyl)amino]-5-[3-[2-fluoro-4-[3-(methylamino)prop-1-ynyl]phenoxy]propyl]thiazole-4-carboxylic acid,
- 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-(2,3-dihydroxypropyl)amino]-5-[3-[2-fluoro-4-[3-(methylamino)prop-1-ynyl]phenoxy]propyl]thiazole-4-carboxylic acid,
- 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-(4,5-dihydroxypentyl)amino]-5-[3-[2-fluoro-4-[3-(methylamino)prop-1-ynyl]phenoxy]propyl]thiazole-4-carboxylic acid,
- 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-(3,4-dihydroxybutyl)amino]-5-[3-[4-[3-(dimethylamino)prop-1-ynyl]-2-fluoro-phenoxy]propyl]thiazole-4-carboxylic acid,
- 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-(3-hydroxypropyl)amino]-5-[3-[2-fluoro-4-[3-(methylamino)prop-1-ynyl]phenoxy]propyl]thiazole-4-carboxylic acid,
- 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-[4-hydroxy-5-(trimethylammonio)pentyl]amino]-5-[3-[2-fluoro-4-[3-(methylamino)prop-1-ynyl]phenoxy]propyl]thiazole-4-carboxylate,
- 3-[[5-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-[4-carboxy-5-[3-[2-fluoro-4-[3-(methylamino)prop-1-ynyl]phenoxy]propyl]thiazol-2-yl]amino]-2-hydroxy-pentyl]-dimethyl-ammonio]propane-1-sulfonate,
- 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-(4-hydroxybutyl)amino]-5-[3-[2-fluoro-4-[3-[methyl(3-sulfopropyl)amino]prop-1-ynyl]phenoxy]propyl]thiazole-4-carboxylic acid,
- 5-{1-[(Adamantan-1-yl)methyl]-5-methyl-1*H*-pyrazol-4-yl}-2-({6-[(1,3-benzothiazol-2-yl)amino]-5-methylpyridazin-3-yl}(methyl)amino)-1,3-thiazole-4-carboxylic acid,
- 5-{1-[(Adamantan-1-yl)methyl]-5-methyl-1*H*-pyrazol-4-yl}-2-({6-[(1,3-benzothiazol-2-yl)amino]-5-cyclopropylpyridazin-3-yl}(methyl)amino)-1,3-thiazole-4-carboxylic acid,
- 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-[5-[2-(diethylamino)ethylamino]-4-hydroxy-pentyl]amino]-5-[3-[4-[3-(dimethylamino)prop-1-ynyl]-2-fluoro-phenoxy]propyl]thiazole-4-carboxylic acid,

- 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-[5-[2-(4-methylpiperazin-1-yl)ethylamino]pentyl]amino]-5-[3-[4-[3-(dimethylamino)prop-1-ynyl]-2-fluoro-phenoxy]propyl]thiazole-4-carboxylic acid,
- 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-(4-hydroxy-5-piperazin-1-yl-pentyl)amino]-5-[3-[4-[3-(dimethylamino)prop-1-ynyl]-2-fluoro-phenoxy]propyl]thiazole-4-carboxylic acid,
- 2-({6-[(1,3-Benzothiazol-2-yl)amino]-5-methylpyridazin-3-yl}(methyl)amino)-5-[(2*S*)-3-{4-[3-(dimethylamino)prop-1-yn-1-yl]-2-fluorophenoxy}-2-methylpropyl]-1,3-thiazole-4-carboxylic acid,
- 2-[4-Aminobutyl-[6-(1,3-benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]amino]-5-[3-[4-[3-(dimethylamino)prop-1-ynyl]-2-fluoro-phenoxy]propyl]thiazole-4-carboxylic acid,
- 2-[5-Aminopentyl-[6-(1,3-benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]amino]-5-[3-[4-[3-(dimethylamino)prop-1-ynyl]-2-fluoro-phenoxy]propyl]thiazole-4-carboxylic acid,
- 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-[3-(dimethylamino)propyl]amino]-5-[3-[2-fluoro-4-[3-(methylamino)prop-1-ynyl]phenoxy]propyl]thiazole-4-carboxylic acid,
- 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-methyl-amino]-5-[3-[4-[3-(dimethylamino)but-1-ynyl]-2-fluoro-phenoxy]propyl]thiazole-4-carboxylic acid,
- 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-[4-hydroxy-5-(trimethylammonio)pentyl]amino]-5-[3-[4-[3-(dimethylamino)prop-1-ynyl]-2-fluoro-phenoxy]propyl]thiazole-4-carboxylate,
- 3-[2-[3-[4-[3-[2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-methyl-amino]-4-carboxy-thiazol-5-yl]propoxy]-3-fluoro-phenyl]prop-2-ynylamino]ethyl-dimethyl-ammonio]propane-1-sulfonate,
- 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-[4-hydroxy-5-(4-methylmorpholin-4-ium-4-yl)pentyl]amino]-5-[3-[4-[3-(dimethylamino)prop-1-ynyl]-2-fluoro-phenoxy]propyl]thiazole-4-carboxylate,
- 2-[3-[4-[3-[2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-methyl-amino]-4-carboxy-thiazol-5-yl]propoxy]-3-fluoro-phenyl]prop-2-ynylamino]ethyl-trimethyl-ammonium,
- 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-[6-(trimethylammonio)hexyl]amino]-5-[3-[2-fluoro-4-[3-(methylamino)prop-1-ynyl]phenoxy]propyl]thiazole-4-carboxylate,
- 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-[5-[2-

- hydroxyethyl(dimethyl)ammonio]pentyl]amino]-5-[3-[4-[3-(dimethylamino)prop-1-ynyl]-2-fluoro-phenoxy]propyl]thiazole-4-carboxylate,
- 5 - 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-[5-[carboxymethyl(dimethyl)ammonio]pentyl]amino]-5-[3-[4-[3-(dimethylamino)prop-1-ynyl]-2-fluoro-phenoxy]propyl]thiazole-4-carboxylate,
- 3-[[5-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-[4-carboxy-5-[3-[2-fluoro-4-[(*E*)-3-oxoprop-1-enyl]phenoxy]propyl]thiazol-2-yl]amino]-2-hydroxy-pentyl]-dimethyl-ammonio]propane-1-sulfonate,
- 10 - 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-methyl-amino]-5-[3-[4-[3-(dimethylamino)prop-1-ynyl]phenoxy]propyl]thiazole-4-carboxylic acid,
- 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-methyl-amino]-5-[3-[4-[1-[(dimethylamino)methyl]-3-bicyclo[1.1.1]pentanyl]phenoxy]propyl]thiazole-4-carboxylic acid,
- 2-[[6-(1,3-Benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-(3-phosphonopropyl)amino]-5-[3-[2-fluoro-4-[3-(methylamino)prop-1-ynyl]phenoxy]propyl]thiazole-4-carboxylic acid,
- 15 - 2-({6-[(1,3-Benzothiazol-2-yl)amino]-5-methylpyridazin-3-yl}(3-carboxypropyl)amino)-5-(3-{4-[3-(dimethylamino)prop-1-yn-1-yl]-2-fluorophenoxy}propyl)-1,3-thiazole-4-carboxylic acid,
- 2-({6-[(1,3-Benzothiazol-2-yl)amino]-5-methylpyridazin-3-yl}(3-phosphonopropyl)amino)-5-(3-{4-[3-(dimethylamino)prop-1-yn-1-yl]-2-fluorophenoxy}propyl)-1,3-thiazole-4-carboxylic acid,
- 20 - 2-({6-[(1,3-Benzothiazol-2-yl)amino]-5-methylpyridazin-3-yl}(3-sulfopropyl)amino)-5-(3-{4-[3-(dimethylamino)prop-1-yn-1-yl]-2-fluorophenoxy}propyl)-1,3-thiazole-4-carboxylic acid,
- 2-({6-[(1,3-Benzothiazol-2-yl)amino]-5-methylpyridazin-3-yl}(4-sulfobutyl)amino)-5-(3-{4-[3-(dimethylamino)prop-1-yn-1-yl]-2-fluorophenoxy}propyl)-1,3-thiazole-4-carboxylic acid,
- 25 - 2-({6-[(1,3-Benzothiazol-2-yl)amino]-5-methylpyridazin-3-yl}(4-phosphonobutyl)amino)-5-(3-{4-[3-(dimethylamino)prop-1-yn-1-yl]-2-fluorophenoxy}propyl)-1,3-thiazole-4-carboxylic acid,
- 2-({6-[(1,3-Benzothiazol-2-yl)amino]-5-methylpyridazin-3-yl}(4-carboxybutyl)amino)-5-(3-{4-[3-(dimethylamino)prop-1-yn-1-yl]-2-fluorophenoxy}propyl)-1,3-thiazole-4-carboxylic acid,
- 30 - 2-[{6-[(1,3-benzothiazol-2-yl)amino]-5-methylpyridazin-3-yl}(pent-4-yn-1-yl)amino]-5-(3-{2-fluoro-4-[3-(methylamino)prop-1-yn-1-yl]phenoxy}propyl)-1,3-thiazole-4-carboxylic

acid,

- 2-({6-[(1,3-Benzothiazol-2-yl)amino]-5-methylpyridazin-3-yl}(methyl)amino)-5-{3-[2-fluoro-4-(3-{methyl[2-(methylamino)ethyl]amino}prop-1-yn-1-yl)phenoxy]propyl}-1,3-thiazole-4-carboxylic acid,
 - 5 - 2-({6-[(1,3-Benzothiazol-2-yl)amino]-5-methylpyridazin-3-yl}(methyl)amino)-5-[3-(2-fluoro-4-{3-[(2-hydroxyethyl)(methyl)amino]prop-1-yn-1-yl}phenoxy)propyl]-1,3-thiazole-4-carboxylic acid,
 - 2-({6-[(1,3-Benzothiazol-2-yl)amino]-5-methylpyridazin-3-yl}(methyl)amino)-5-{3-[2-fluoro-4-(3-hydroxyprop-1-yn-1-yl)phenoxy]propyl}-1,3-thiazole-4-carboxylic acid,
 - 10 - 2-[5-azidopentyl-[6-[(1,3-benzothiazol-2-yl)amino]-5-methyl-pyridazin-3-yl]amino]-5-[3-[2-fluoro-4-[3-(methylamino)prop-1-ynyl]phenoxy]propyl]-1,3-thiazole-4-carboxylic acid,
- its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.

30. A compound according to claim 1 selected in the following group:

- 15 - 6-[{6-[(1,3-benzothiazol-2-yl)amino]-5-methylpyridazin-3-yl}(methyl)amino]-3-[1-({3-[2-(dimethylamino)ethoxy]-5,7-dimethyladamantan-1-yl}methyl)-5-methyl-1*H*-pyrazol-4-yl]pyridine-2-carboxylic acid,
- 6-[[6-(1,3-benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-methyl-amino]-3-[1-[[3-[2-(3-hydroxypropylamino)ethoxy]-5,7-dimethyl-1-adamantyl]methyl]-5-methyl-pyrazol-4-
- 20 - yl]pyridine-2-carboxylic acid,
- 6-[[6-(1,3-benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-methyl-amino]-3-[1-[[3-[2-(3-methoxypropylamino)ethoxy]-5,7-dimethyl-1-adamantyl]methyl]-5-methyl-pyrazol-4-
- yl]pyridine-2-carboxylic acid,
- 25 - 6-[{6-[(1,3-benzothiazol-2-yl)amino]-5-methylpyridazin-3-yl}(methyl)amino]-3-(1-{[3-(2-{[(3*S*)-3,4-dihydroxybutyl]amino}ethoxy)-5,7-dimethyladamantan-1-yl]methyl}-5-methyl-1*H*-pyrazol-4-yl)pyridine-2-carboxylic acid,
- 6-[[6-(1,3-benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-methyl-amino]-3-[1-[[3,5-dimethyl-7-(2-morpholinoethoxy)-1-adamantyl]methyl]-5-methyl-pyrazol-4-yl]pyridine-2-
- 30 - carboxylic acid,
- 6-[[6-(1,3-benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-methyl-amino]-3-[1-[[3-[2-(2-carboxyethylamino)ethoxy]-5,7-dimethyl-1-adamantyl]methyl]-5-methyl-pyrazol-4-
- yl]pyridine-2-carboxylic acid,
- 6-[[6-(1,3-benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-methyl-amino]-3-[1-[[3-[2-(3-

hydroxyphenyl)methylamino]ethoxy]-5,7-dimethyl-1-adamantyl)methyl]-5-methyl-pyrazol-4-yl]pyridine-2-carboxylic acid,

- 2-[[6-(1,3-benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-methyl-amino]-5-[3-[4-[3-(dimethylamino)prop-1-ynyl]-2-fluoro-phenoxy]propyl]thiazole-4-carboxylic acid,
- 2-[[6-(1,3-benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-(3-hydroxypropyl)amino]-5-[3-[2-fluoro-4-[3-(methylamino)prop-1-ynyl]phenoxy]propyl]thiazole-4-carboxylic acid,
- 2-[[6-(1,3-benzothiazol-2-ylamino)-5-methyl-pyridazin-3-yl]-methyl-amino]-5-[3-[2-fluoro-4-(3-pyrrolidin-1-ylprop-1-ynyl)phenoxy]propyl]thiazole-4-carboxylic acid,

its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.

31. Pharmaceutical composition comprising a compound according to any of claims 1 to 30, or an addition salt thereof with a pharmaceutically acceptable acid or base in combination with one or more pharmaceutically acceptable excipients.

32. Pharmaceutical composition according to claim 31 for use as pro-apoptotic agents.


33. Pharmaceutical composition according to claim 31 for use in the treatment of cancers, autoimmune diseases or immune system diseases.

34. Pharmaceutical composition for use according to claim 33 wherein the cancer is an haematological malignancy or a solid tumor.

35. Pharmaceutical composition for use according to claim 34 wherein the haematological malignancy is myeloma, especially multiple myeloma, lymphoma, especially Non-Hodgkin Lymphoma (NHL), or leukemia, especially Chronic Lymphocytic Leukemia (CLL), T-cell Acute Lymphoblastic Leukemia (T-ALL), B-cell Acute Lymphoblastic Leukemia (B-ALL) and Acute Myelogenous Leukemia (AML).

36. Pharmaceutical composition for use according to claim 34 wherein the solid tumor is selected from bladder, brain, breast, uterus, oesophagus and liver cancers, colorectal cancer, renal cancer, melanoma, ovarian cancer, prostate cancer, pancreatic cancer and lung cancer.

- 37.** Compound according to any of claims 1 to 30, or an addition salt thereof with a pharmaceutically acceptable acid or base, for use in the treatment of a cancer selected from: myeloma, especially multiple myeloma, lymphoma, especially Non-Hodgkin Lymphoma (NHL), or leukemia, especially Chronic Lymphocytic Leukemia (CLL), T-cell Acute Lymphoblastic Leukemia (T-ALL), B-cell Acute Lymphoblastic Leukemia (B-ALL) and Acute Myelogenous Leukemia (AML), bladder, brain, breast, uterus, oesophagus and liver cancers, colorectal cancer, renal cancer, melanoma, ovarian cancer, prostate cancer, pancreatic cancer and lung cancer, especially non-small-cell lung cancer and small-cell lung cancer.
- 38.** Combination of a compound according to any of claims 1 to 30, with an anti-cancer agent selected from genotoxic agents, mitotic poisons, anti-metabolites, proteasome inhibitors, kinase inhibitors and antibodies.
- 39.** Pharmaceutical composition comprising a combination according to claim 38 in combination with one or more pharmaceutically acceptable excipients.
- 40.** Combination according to claim 38 for use in the treatment of cancers.
- 41.** Compound according to any of claims 1 to 30, for use in the treatment of cancers requiring radiotherapy.
- ~~**42.** Pharmaceutical composition according to claim 31 for use in the treatment of diseases or conditions characterized by an excess or a deregulated activity of platelets, especially pro-thrombotic conditions.~~
- 43,42.** Synthesis intermediate which is:



wherein R_4 and m are as defined in general formula (I), preferably R_4 represents a hydrogen atom.